Anthropic Overtakes OpenAI on Revenue at $47bn Run Rate — and Launches Claude Science

Six months ago, OpenAI was the undisputed revenue leader in AI. That has changed. Anthropic has overtaken OpenAI on self-reported annualised revenue, with a run rate of $47 billion against OpenAI’s reported $25–33 billion. It also now leads on business subscriptions — the metric that arguably matters most for long-term commercial durability. On top of that, Anthropic just launched Claude Science, a research workbench that could change how scientists and analysts use AI tools. UK businesses and researchers need to pay attention to what this shift actually means.

The Revenue Reversal — What the Numbers Say

Anthropic’s $47 billion annualised run rate represents an extraordinary trajectory for a company that only launched Claude as a commercial product in early 2023. OpenAI’s reported run rate of $25–33 billion is still a very large number — but the gap between the two is now meaningful and, by all accounts, widening.

A caveat worth noting: these are self-reported figures, not audited revenue. Both companies define annualised run rate by taking recent monthly revenue and multiplying by 12. The methodology can be generous if recent months were unusually strong. Neither company is yet profitable enough that these figures face the scrutiny of public company reporting.

That said, even discounting for optimistic accounting, the direction is clear. Anthropic is winning enterprise deals at a scale that now exceeds ChatGPT’s business revenue. The product-market fit in business settings — particularly for long-document analysis, coding assistance, and research workflows — is stronger than Anthropic’s public profile sometimes suggests.

Why Enterprise AI Customers Are Choosing Claude

When I ask UK businesses why they use Claude rather than ChatGPT, a few reasons come up consistently. First, the model is perceived as more reliable on complex reasoning tasks — less likely to confidently give you a wrong answer. Second, Claude’s longer context window has historically been an advantage for businesses dealing with large documents. Third, Anthropic’s enterprise sales and support motion has been aggressive in a way that OpenAI’s was not until recently.

The subscription lead on business accounts matters because subscriptions are stickier than API usage. A business that integrates Claude into its internal tools is not going to switch provider lightly. The switching costs are real — integration work, workflow retraining, potentially different output formats. Once you are in, you tend to stay in, at least for a year or two.

OpenAI is not standing still. The GPT-5.6 family (delayed for now by US government oversight requests) and GPT-Live, which launched on 8 July, suggest OpenAI is still pushing hard on product. GPT-Live targets real-time voice interaction — a use case where OpenAI has an established lead. The competition is intensifying, not slowing.

Claude Science — What It Is and Who It Is For

Claude Science is not a new model. It is a new interface — a research workbench built on top of existing Claude models, specifically designed for scientific and research workflows. It launched in beta this week, available to Pro, Max, Team, and Enterprise subscribers.

The workbench includes more than 60 preconfigured tools. These cover scientific literature search and summarisation, experimental design assistance, statistical analysis, citation verification, data interpretation, and hypothesis generation. The goal is to make Claude genuinely useful for practising scientists — not just academics writing summaries, but researchers actively working through data and methodology questions.

UK research institutions — universities, NHS research departments, biotech companies — should pay attention to this. The bottleneck in research is rarely a shortage of ideas. It is time spent on literature review, data cleaning, statistical checking, and writing. If Claude Science reliably accelerates any of those, it creates real value.

Anthropic’s Drug Discovery Programme — A Serious Research Bet

Alongside Claude Science, Anthropic announced an internal drug discovery programme targeting neglected tropical diseases — conditions like sleeping sickness, Chagas disease, and river blindness that affect hundreds of millions of people in developing countries but attract minimal commercial pharmaceutical interest because sufferers cannot pay for treatment.

This is an unusual choice for a commercial AI company. Most AI-in-drug-discovery projects are aimed at conditions where there is clear commercial return. Neglected diseases represent the opposite of that. Anthropic’s framing is that this is both a demonstration of what AI can do in research settings and a public commitment to applying the technology where market forces would otherwise fail to.

UK researchers and biotech investors should watch how this programme develops. If Anthropic’s AI tools can identify meaningful drug candidates for neglected diseases — even one — it would be a landmark demonstration of AI’s scientific capability that goes well beyond benchmark tests and coding evaluations.

The White House AI Standards Framework — What Is Being Negotiated

Both OpenAI and Anthropic are currently in advanced talks with the White House to finalise voluntary standards for frontier AI model releases. The framework would establish testing timelines, access rules, and safety benchmarks that labs must meet before launching advanced models publicly. An announcement was expected this week.

This matters because it signals that both companies — despite their different postures on safety and commercialisation — are willing to engage with government oversight rather than resist it. The alternative, where labs release models without pre-agreement with governments, was always going to result in mandatory regulation eventually. Voluntary standards, if they stick, give the industry more control over what those standards look like.

UK businesses should follow this closely. If the US establishes voluntary standards that become de facto global norms — as US tech standards often do — UK AI deployments will need to comply with whatever framework emerges. That could affect procurement decisions, particularly for organisations in regulated industries like financial services, healthcare, and public services.

Google’s Gemini 2.5 Pro Is Also Competitive

While Anthropic and OpenAI dominate the business conversation, Google’s Gemini 2.5 Pro with Deep Think reasoning mode hit strong benchmark results this week — 82.4% on GPQA Diamond, surpassing both GPT-5.5 and Fable 5 on science benchmarks. Its two-million-token context window is the largest available at scale.

For UK businesses already deeply embedded in Google Workspace — which covers a large proportion of UK SMEs and public sector organisations — Gemini 2.5 Pro represents the path of least resistance for AI adoption. It integrates directly into Gmail, Docs, Sheets, and Meet without additional setup. That convenience advantage is not nothing.

The competition between Anthropic, OpenAI, and Google means UK businesses are in a genuinely good position as buyers. Three very capable providers are competing aggressively on price, capability, and enterprise features. That competition is likely to intensify further as GPT-5.6 eventually launches and Anthropic continues to scale its enterprise motion.

What Anthropic’s Revenue Lead Means for UK AI Investment

For UK investors watching the private AI market, Anthropic’s revenue overtake is significant for a different reason. Anthropic is reportedly targeting a valuation of £700 billion-plus in its next fundraise. That is an enormous number — comparable to established FTSE 100 giants — for a company that is not yet profitable.

Whether that valuation is justified depends on whether the revenue growth is sustainable and whether Anthropic can translate its enterprise lead into durable market share. The history of enterprise software suggests that companies which win the early enterprise adoption phase tend to hold those positions for years. But AI is evolving so fast that past patterns may not hold.

UK investors cannot currently access Anthropic shares directly — the company remains private. Indirect exposure is available through stakes in SoftBank, which has invested in Anthropic, or through UK-listed companies with significant Anthropic integrations in their product stack. The IPO timeline remains uncertain, but if Anthropic follows through on its reported plans, a public listing could come within 12–18 months.

What This Means for UK Businesses Using AI Tools

The practical takeaway for UK businesses is that the AI landscape in mid-2026 is more competitive — and more uncertain in terms of who will lead — than it was 12 months ago. OpenAI has been displaced from the revenue top position. Google is competitive on science benchmarks. Anthropic is winning enterprise subscriptions. And GPT-5.6, once it launches, could shift the picture again.

For procurement decisions, this reinforces the advice to prioritise your specific workflow fit over brand or benchmark performance. Test the models on your actual tasks. The differences between top-tier models on most business tasks are smaller than the marketing suggests. The differences in pricing, support quality, and integration capability can be more significant.

For researchers specifically, Claude Science is worth evaluating as soon as it becomes available. The combination of 60+ preconfigured scientific tools and a model with strong long-context reasoning capability could genuinely change how literature reviews and data analysis workflows operate.

This article is for educational purposes only and does not constitute financial or investment advice. AI tool decisions should be made based on your specific business needs and requirements.